{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:54:33Z","timestamp":1793044473437,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T00:00:00Z","timestamp":1679011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T00:00:00Z","timestamp":1679011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s00066-023-02065-x","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T21:05:49Z","timestamp":1679864749000},"page":"838-846","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Role of palliative SBRT in barcelona clinic liver cancer-stage\u00a0C hepatocellular carcinoma patients"],"prefix":"10.1007","volume":"199","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9911-3384","authenticated-orcid":false,"given":"Deepti","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Thaper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanuman Prasad","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,17]]},"reference":[{"issue":"3","key":"2065_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung\u00a0H, Ferlay\u00a0J, Siegel\u00a0RL, Laversanne\u00a0M, Soerjomataram\u00a0I, Jemal\u00a0A et\u00a0al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"2065_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/hepr.13438","volume":"50","author":"M Kudo","year":"2020","unstructured":"Kudo\u00a0M, Izumi\u00a0N, Kubo\u00a0S, Kokudo\u00a0N, Sakamoto\u00a0M, Shiina\u00a0S et al (2020) Report of the 20th Nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res 50:15\u201346","journal-title":"Hepatol Res"},{"issue":"26","key":"2065_CR3","doi-asserted-by":"publisher","first-page":"40816","DOI":"10.18632\/oncotarget.8386","volume":"7","author":"S Cheng","year":"2016","unstructured":"Cheng\u00a0S, Yang\u00a0J, Shen\u00a0F, Zhou\u00a0W, Wang\u00a0Y, Cong\u00a0W et\u00a0al (2016) Multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus\u2014Eastern Hepatobiliary Surgical Hospital consensus statement. Oncotarget 7(26):40816\u201340829. https:\/\/doi.org\/10.18632\/oncotarget.8386","journal-title":"Oncotarget"},{"issue":"13","key":"2065_CR4","doi-asserted-by":"publisher","first-page":"e19660","DOI":"10.1097\/MD.0000000000019660","volume":"99","author":"J Que","year":"2020","unstructured":"Que\u00a0J, Wu\u00a0HC, Lin\u00a0CH, Huang\u00a0CI, Li\u00a0LC, Ho\u00a0CH (2020) Comparison of stereotactic body radiation therapy with and without sorafenib as treatment for hepatocellular carcinoma with portal vein tumor thrombosis. Medicine (Baltimore) 99(13):e19660. https:\/\/doi.org\/10.1097\/MD.0000000000019660","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"2065_CR5","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3390\/cancers13020192","volume":"13","author":"LA P\u00e9rez-Romasanta","year":"2021","unstructured":"P\u00e9rez-Romasanta\u00a0LA, Gonz\u00e1lez-Del Portillo\u00a0E, Rodr\u00edguez-Guti\u00e9rrez\u00a0A, Mat\u00edas-P\u00e9rez \u00c1 (2021) Stereotactic radiotherapy for hepatocellular carcinoma, radiosensitization strategies and radiation-immunotherapy combination. Cancers (Basel) 13(2):192. https:\/\/doi.org\/10.3390\/cancers13020192","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2065_CR6","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1186\/s12885-016-2894-9","volume":"16","author":"TS Su","year":"2016","unstructured":"Su\u00a0TS, Lu\u00a0HZ, Cheng\u00a0T, Zhou\u00a0Y, Huang\u00a0Y, Gao\u00a0YC et al (2016) Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5\u202fcm. BMC Cancer 16(1):834. https:\/\/doi.org\/10.1186\/s12885-016-2894-9","journal-title":"BMC Cancer"},{"issue":"1","key":"2065_CR7","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s13014-018-1136-5","volume":"13","author":"Y Shui","year":"2018","unstructured":"Shui\u00a0Y, Yu\u00a0W, Ren\u00a0X, Guo\u00a0Y, Xu\u00a0J, Ma\u00a0T, Zhang\u00a0B, Wu\u00a0J, Li\u00a0Q, Hu\u00a0Q, Shen\u00a0L, Bai\u00a0X, Liang\u00a0T, Wei\u00a0Q (2018) Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis. Radiat Oncol 13(1):188. https:\/\/doi.org\/10.1186\/s13014-018-1136-5","journal-title":"Radiat Oncol"},{"key":"2065_CR8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.12809\/hkjr2117253","volume":"24","author":"CKK Choi","year":"2021","unstructured":"Choi\u00a0CKK, Ho\u00a0CHM, Wong\u00a0MYP, Leung\u00a0RWK, Wong\u00a0FCS, Tung\u00a0SY et al (2021) Long-term results of palliative stereotactic radiotherapy of barcelona clinic liver cancer stage C hepatitis B\u2013related hepatocellular carcinoma. Hong Kong J Radiol 24:81\u201386","journal-title":"Hong Kong J Radiol"},{"key":"2065_CR9","volume-title":"Radiation therapy oncology group Rtog 1112 randomized phase iii study of sorafenib versus stereotactic body radiation therapy followed by sorafenib in hepatocellular carcinoma","author":"LA Dawson","year":"2012","unstructured":"Dawson\u00a0LA, Zhu\u00a0A, Knox\u00a0J et\u00a0al (2012) Radiation therapy oncology group Rtog 1112 randomized phase iii study of sorafenib versus stereotactic body radiation therapy followed by sorafenib in hepatocellular carcinoma"},{"key":"2065_CR10","unstructured":"Cancer Institute N (2017) Common Terminology Criteria for Adverse Events (CTCAE) v5.0. https:\/\/www.meddra.org\/. Accessed 4 Nov 2018"},{"issue":"1","key":"2065_CR11","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni\u00a0R, Llovet\u00a0JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30(1):52\u201360. https:\/\/doi.org\/10.1055\/s-0030-1247132","journal-title":"Semin Liver Dis"},{"key":"2065_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.018","author":"M Reig","year":"2021","unstructured":"Reig\u00a0M, Forner\u00a0A, Rimola\u00a0J, Ferrer-F\u00e0brega\u00a0J, Burrel\u00a0M, Garcia-Criado \u00c1 et al (2021) BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J\u00a0Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.018","journal-title":"J Hepatol"},{"issue":"1","key":"2065_CR13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.prro.2021.09.004","volume":"12","author":"S Apisarnthanarax","year":"2022","unstructured":"Apisarnthanarax\u00a0S, Barry\u00a0A, Cao\u00a0M, Czito\u00a0B, DeMatteo\u00a0R, Drinane\u00a0M et\u00a0al (2022) External beam radiation therapy for primary liver cancers: an ASTRO clinical practice guideline. Pract Radiat Oncol 12(1):28\u201351. https:\/\/doi.org\/10.1016\/j.prro.2021.09.004","journal-title":"Pract Radiat Oncol"},{"key":"2065_CR14","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1053\/j.gastro.2007.04.061","volume":"132","author":"HB El-Serag","year":"2007","unstructured":"El-Serag\u00a0HB, Rudolph\u00a0KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557\u20132576","journal-title":"Gastroenterology"},{"issue":"1","key":"2065_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.4103\/ijri.IJRI_352_18","volume":"29","author":"Y Patidar","year":"2019","unstructured":"Patidar\u00a0Y, Garg\u00a0L, Mukund\u00a0A, Sarin\u00a0SK (2019) Early experience of combination therapy of transarterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma measuring 3\u20137\u202fcm. Indian J Radiol Imaging 29(1):47\u201352. https:\/\/doi.org\/10.4103\/ijri.IJRI_352_18","journal-title":"Indian J Radiol Imaging"},{"issue":"1101","key":"2065_CR16","doi-asserted-by":"publisher","first-page":"20181053","DOI":"10.1259\/bjr.20181053","volume":"92","author":"S Chopra","year":"2019","unstructured":"Chopra\u00a0S, George\u00a0K, Engineer\u00a0R, Rajamanickam\u00a0K, Nojin\u00a0S, Joshi\u00a0K et\u00a0al (2019) Stereotactic body radio therapy for inoperable large hepatocellular cancers: results from a\u00a0clinical audit. Br J Radiol 92(1101):20181053. https:\/\/doi.org\/10.1259\/bjr.20181053","journal-title":"Br J Radiol"},{"key":"2065_CR17","doi-asserted-by":"publisher","first-page":"872","DOI":"10.3390\/cancers12040872","volume":"12","author":"KW Yeoh","year":"2020","unstructured":"Yeoh\u00a0KW, Prawir\u00a0A, Bin Saad\u00a0MZ, Lee\u00a0KM, Lee\u00a0EMH, Low\u00a0GK et\u00a0al (2020) Vinorelbine augments radiotherapy in hepatocellular carcinoma. Cancers 12:872","journal-title":"Cancers"},{"key":"2065_CR18","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1200\/JCO.2012.44.1659","volume":"31","author":"A Bujold","year":"2013","unstructured":"Bujold\u00a0A, Massey\u00a0CA, Kim\u00a0JJ, Brierley\u00a0J, Cho\u00a0C, Wong\u00a0RK et\u00a0al (2013) Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J\u00a0Clin Oncol 31:1631\u20131639","journal-title":"J Clin Oncol"},{"issue":"1","key":"2065_CR19","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ijrobp.2017.12.288","volume":"110","author":"N Ohri","year":"2021","unstructured":"Ohri\u00a0N, Tome\u00a0WA, Mendez Romero\u00a0A, Miften\u00a0M, Ten Haken\u00a0RK, Dawson\u00a0LA et\u00a0al (2021) Local control after stereotactic body radiation therapy for liver tumors. Int J Radiat Oncol Biol Phys 110(1):188\u2013195. https:\/\/doi.org\/10.1016\/j.ijrobp.2017.12.288","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2065_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-017-0851-7","author":"E Gkika","year":"2017","unstructured":"Gkika\u00a0E, Schultheiss\u00a0M, Bettinger\u00a0D, Maruschke\u00a0L, Neeff\u00a0HP, Schulenburg\u00a0M et\u00a0al (2017) Excellent local control and tolerance profile after stereotactic body radiotherapy of advanced hepatocellular carcinoma. Radiat Oncol. https:\/\/doi.org\/10.1186\/s13014-017-0851-7","journal-title":"Radiat Oncol"},{"issue":"1","key":"2065_CR21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.21037\/apm.2016.11.02","volume":"6","author":"AY Hammad","year":"2017","unstructured":"Hammad\u00a0AY, Robbins\u00a0JR, Turaga\u00a0KK, Christians\u00a0KK, Gamblin\u00a0TC, Johnston\u00a0FM (2017) Palliative interventions for hepatocellular carcinoma patients: analysis of the National Cancer Database. Ann Palliat Med 6(1):26\u201335. https:\/\/doi.org\/10.21037\/apm.2016.11.02","journal-title":"Ann Palliat Med"},{"key":"2065_CR22","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1002\/cncr.21811","volume":"106","author":"MA Hawkins","year":"2006","unstructured":"Hawkins\u00a0MA, Dawson\u00a0LA (2006) Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer 106:1653\u20131663","journal-title":"Cancer"},{"issue":"3","key":"2065_CR23","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/jrr\/rru130","volume":"56","author":"H Yamashita","year":"2015","unstructured":"Yamashita\u00a0H, Onishi\u00a0H, Murakami\u00a0N, Matsumoto\u00a0Y, Matsuo\u00a0Y, Nomiya\u00a0T, Nakagawa\u00a0K (2015) Japanese Radiological Society multi-institutional SBRT study group (JRS-SBRTSG). Survival outcomes after stereotactic body radiotherapy for 79 Japanese patients with hepatocellular carcinoma. J\u00a0Radiat Res 56(3):561\u2013567. https:\/\/doi.org\/10.1093\/jrr\/rru130","journal-title":"J Radiat Res"},{"key":"2065_CR24","doi-asserted-by":"publisher","first-page":"e9249","DOI":"10.1097\/MD.0000000000009249","volume":"96","author":"H-T Kuo","year":"2017","unstructured":"Kuo\u00a0H\u2011T, Que\u00a0J, Lin\u00a0L\u2011C, Yang\u00a0C\u2011C, Koay\u00a0L\u2011B, Lin\u00a0C\u2011H (2017) Impact of tumor size on outcome after stereotactic body radiation therapy for inoperable hepatocellular carcinoma. Medicine 96:e9249. https:\/\/doi.org\/10.1097\/MD.0000000000009249","journal-title":"Medicine"},{"issue":"1","key":"2065_CR25","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12885-019-5362-5","volume":"19","author":"RJ Klement","year":"2019","unstructured":"Klement\u00a0RJ, Abbasi-Senger\u00a0N, Adebahr\u00a0S, Alheid\u00a0H, Allgaeuer\u00a0M, Becker\u00a0G et al (2019) The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a\u00a0combined analysis of 388\u00a0patients with 500 metastases. BMC Cancer 19(1):173. https:\/\/doi.org\/10.1186\/s12885-019-5362-5","journal-title":"BMC Cancer"},{"issue":"1","key":"2065_CR26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng\u00a0AL, Kang\u00a0YK, Chen\u00a0Z, Tsao\u00a0CJ, Qin\u00a0S, Kim\u00a0JS et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a\u00a0phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(1):25\u201334. https:\/\/doi.org\/10.1016\/S1470-2045(08)70285-7","journal-title":"Lancet Oncol"},{"key":"2065_CR27","doi-asserted-by":"publisher","first-page":"379","DOI":"10.18203\/2320-6012.ijrms20170039","volume":"5","author":"MI Nandennavar","year":"2017","unstructured":"Nandennavar\u00a0MI, Karpurmath\u00a0SV, Mandakalatur\u00a0G, Prasad\u00a0AE (2017) Clinical profile of hepatocellular carcinoma and experience with sorafenib from a\u00a0tertiary cancer centre in Southern India. Int J Res Med Sci 5:379\u2013383","journal-title":"Int J Res Med Sci"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-023-02065-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-023-02065-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-023-02065-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T13:05:30Z","timestamp":1692882330000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-023-02065-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,17]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["2065"],"URL":"https:\/\/doi.org\/10.1007\/s00066-023-02065-x","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,17]]},"assertion":[{"value":"14 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.\u00a0Sharma, D.\u00a0Thaper, R.\u00a0Kamal and H.P.\u00a0Yadav declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}